HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Sidney Levitsky Frank W. Sellke Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bianchi, C. Articles by Sellke, F. W. Search for Related Content PubMed PubMed Citation Articles by Bianchi, C. Articles by Sellke, F. W. Related Collections Myocardial protection

Ann Thorac Surg 2002;74:1201-1207
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs

^a Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
^b Inotek Corporation, Beverly, Massachusetts, USA

Accepted for publication June 26, 2002.

* Address reprint requests to Dr Sellke, Beth Israel Deaconess Medical Center, 110 Francis St, LMOB Suite 2A, Boston, MA02215, USA.
e-mail: fsellke{at}caregroup.harvard.edu

BACKGROUND: Reactive oxygen and nitrogen species generated after reperfusion injury result in organ dysfunction. Peroxynitrite, a reactive nitrogen molecule produced from the reaction of superoxide anions and nitric oxide, is thought to be a causative agent in oxidative reperfusion injury. The aim of this study was to investigate the effects of a novel peroxynitrite decomposition catalyst (FP-15) in an acute myocardial ischemia/reperfusion model.

METHODS: Pigs were subjected to 60 minutes of regional ischemia by reversibly ligating the left anterior descending coronary artery followed by 180 minutes of reperfusion. In the treatment group (n = 6), an FP-15 (1 mg/kg) bolus was infused through the jugular vein after 30 minutes of ischemia followed by a continuous infusion (1 mg · kg^-1 · h^-1) during reperfusion. Vehicle was infused in the control group (n = 6). Coronary flow was recorded by an ultrasonic flow probe and infarct size determined by tetrazolium staining. Arterial and left ventricular pressures were monitored continuously and regional myocardial function determined by sonomicrometry.

RESULTS: No significant differences were observed in either hemodynamics or ischemic area at risk. However, the infarct size was significantly reduced (35.3% ± 3.5% versus 21.6% ± 2.6% of the ischemic area, control versus FP-15-treated groups, respectively, p < 0.05). +dP/dt was transiently improved in the FP-15-treated groups while during most of the reperfusion period coronary flow, and was significantly lower in the FP-15-treated group as compared to the control group (p < 0.01).

CONCLUSIONS: FP-15 administration reduces myocardial infarct size and reactive hyperemia. These data support the pathogenic role of endogenously produced peroxynitrite and that FP-15 is effective in preventing myocardial reperfusion injury.

This article has been cited by other articles:

				P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF]

				G. M. Pieper, V. Nilakantan, M. Chen, J. Zhou, A. K. Khanna, J. D. Henderson Jr., C. P. Johnson, A. M. Roza, and C. Szabo Protective Mechanisms of a Metalloporphyrinic Peroxynitrite Decomposition Catalyst, WW85, in Rat Cardiac Transplants J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 53 - 60. [Abstract] [Full Text] [PDF]

				T. A. Khan, C. Bianchi, P. Voisine, J. Feng, J. Baker, M. Hart, M. Takahashi, G. Stahl, and F. W. Sellke Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 602 - 608. [Abstract] [Full Text] [PDF]

				G. Szabo and C. Szabo Reply to the Editor J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 324 - 325. [Full Text] [PDF]

				S. Lancel, S. Tissier, S. Mordon, X. Marechal, F. Depontieu, A. Scherpereel, C. Chopin, and R. Neviere Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2348 - 2358. [Abstract] [Full Text] [PDF]

				P. Pacher, L. Liaudet, P. Bai, J. G. Mabley, P. M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M. S. Wolin, et al. Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction Circulation, February 18, 2003; 107(6): 896 - 904. [Abstract] [Full Text] [PDF]